Gay Peter C, Herold Daniel L, Olson Eric J
Mayo Sleep Disorders Center, Mayo Foundation, Rochester, MN 55905, USA.
Sleep. 2003 Nov 1;26(7):864-9. doi: 10.1093/sleep/26.7.864.
To obtain efficacy, objective compliance, and self-assessment data from obstructive sleep apnea syndrome (OSAS) patients treated with continuous positive airway pressure (CPAP) or a novel bilevel (NBL) therapy.
Randomized, controlled, double-blind trial.
Home treatment after diagnosis and titration by split-night polysomnography (PSG) in a sleep laboratory.
Twenty-seven adults (22 men) newly referred for suspected OSAS but without concomitant medical or sleep disorders.
If the subject's apnea-hypopnea index was greater than 10 and less than 100, the CPAP was titrated during PSG and then followed by NBL titration. Treatment was randomly and blindly set to either CPAP or NBL mode for 1 month.
MEASUREMENTS & RESULTS: There were no significant baseline group differences in age, body mass index, apnea-hypopnea index (mean +/- SD, CPAP group vs NBL group of 46.1 +/- 23.1/hour vs 41.8 +/- 25.8), CPAP requirement, or scores on the Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire. Treatment with CPAP and NBL equivalently reduced the apnea-hypopnea index during the laboratory titration (7.6 +/- 11.9/hour vs. 3.7 +/- 4.4, respectively). At 1 month, there were no significant group compliance differences as determined by percentage of nights with at least 4 hours of use (CPAP, 80.5 +/- 24 vs NBL, 77.6 +/- 24.8) and hours of use per night (CPAP, 5.6 +/- 1.4 hours/night vs NBL, 5.6 +/- 1.7). Similar improvements were seen in scores on the Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire.
The NBL appeared to be as effective as CPAP for the treatment of OSAS but offered no advantages in patients receiving first-time therapy for OSAS.
获取阻塞性睡眠呼吸暂停综合征(OSAS)患者接受持续气道正压通气(CPAP)或新型双水平(NBL)治疗后的疗效、客观依从性和自我评估数据。
随机、对照、双盲试验。
在睡眠实验室经分夜多导睡眠图(PSG)诊断和滴定后进行家庭治疗。
27名成年男性(22名男性),新被转诊疑似患有OSAS,但无伴发的内科或睡眠障碍。
如果受试者的呼吸暂停低通气指数大于10且小于100,则在PSG期间对CPAP进行滴定,然后进行NBL滴定。治疗被随机且盲法设定为CPAP或NBL模式,为期1个月。
两组在年龄、体重指数、呼吸暂停低通气指数(平均值±标准差,CPAP组与NBL组分别为46.1±23.1次/小时与41.8±25.8次/小时)、CPAP需求或爱泼沃斯嗜睡量表及睡眠问卷功能结果评分方面,基线无显著差异。在实验室滴定期间,CPAP和NBL治疗等效降低了呼吸暂停低通气指数(分别为7.6±11.9次/小时与3.7±4.4次/小时)。1个月时,通过至少使用4小时的夜晚百分比(CPAP组为80.5±24,NBL组为77.6±24.8)和每晚使用小时数(CPAP组为5.6±1.4小时/晚,NBL组为5.6±1.7小时)确定,两组依从性无显著差异。爱泼沃斯嗜睡量表及睡眠问卷功能结果评分也有类似改善。
NBL在治疗OSAS方面似乎与CPAP一样有效,但对于首次接受OSAS治疗的患者并无优势。